Literature DB >> 8516290

Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.

M M Le Beau1, R Espinosa, W L Neuman, W Stock, D Roulston, R A Larson, M Keinanen, C A Westbrook.   

Abstract

Loss of a whole chromosome 5 or a deletion of its long arm (5q) is a recurring abnormality in malignant myeloid neoplasms. To determine the location of genes on 5q that may be involved in leukemogenesis, we examined the deleted chromosome 5 homologs in a series of 135 patients with malignant myeloid diseases. By comparing the breakpoints, we identified a small segment of 5q, consisting of band 5q31, that was deleted in each patient. This segment has been termed the critical region. Distal 5q contains a number of genes encoding growth factors, hormone receptors, and proteins involved in signal transduction or transcriptional regulation. These include several genes that are good candidates for a tumor-suppressor gene, as well as the genes encoding five hematopoietic growth factors (CSF2, IL3, IL4, IL5, and IL9). By using fluorescence in situ hybridization, we have refined the localization of these genes to 5q31.1 and have determined the order of these genes and of other markers within 5q31. By hybridizing probes to metaphase cells with overlapping deletions involving 5q31, we have narrowed the critical region to a small segment of 5q31 containing the EGR1 gene. The five hematopoietic growth factor genes and seven other genes are excluded from this region. The EGR1 gene was not deleted in nine other patients with acute myeloid leukemia who did not have abnormalities of chromosome 5. By physical mapping, the minimum size of the critical region was estimated to be 2.8 megabases. This cytogenetic map of 5q31, together with the molecular characterization of the critical region, will facilitate the identification of a putative tumor-suppressor gene in this band.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516290      PMCID: PMC46745          DOI: 10.1073/pnas.90.12.5484

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  A radiation hybrid map of 18 growth factor, growth factor receptor, hormone receptor, or neurotransmitter receptor genes on the distal region of the long arm of chromosome 5.

Authors:  J A Warrington; S K Bailey; E Armstrong; O Aprelikova; K Alitalo; G M Dolganov; A S Wilcox; J M Sikela; S F Wolfe; M Lovett
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

2.  Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome.

Authors:  J D Rowley; M O Diaz; R Espinosa; Y D Patel; E van Melle; S Ziemin; P Taillon-Miller; P Lichter; G A Evans; J H Kersey
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 3.  The 5q- abnormality.

Authors:  S D Nimer; D W Golde
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

4.  Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia.

Authors:  J Pedersen-Bjergaard; P Philip; S O Larsen; G Jensen; K Byrsting
Journal:  Blood       Date:  1990-09-15       Impact factor: 22.113

5.  Lithotripsy. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

Review 6.  The approaching era of the tumor suppressor genes.

Authors:  G Klein
Journal:  Science       Date:  1987-12-11       Impact factor: 47.728

Review 7.  The 5q-anomaly.

Authors:  H Van den Berghe; K Vermaelen; C Mecucci; D Barbieri; G Tricot
Journal:  Cancer Genet Cytogenet       Date:  1985-07

8.  Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease.

Authors:  J D Rowley; H M Golomb; J W Vardiman
Journal:  Blood       Date:  1981-10       Impact factor: 22.113

9.  Mapping of human chromosome Xq28 by two-color fluorescence in situ hybridization of DNA sequences to interphase cell nuclei.

Authors:  B J Trask; H Massa; S Kenwrick; J Gitschier
Journal:  Am J Hum Genet       Date:  1991-01       Impact factor: 11.025

10.  Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.

Authors:  M M Le Beau; K S Albain; R A Larson; J W Vardiman; E M Davis; R R Blough; H M Golomb; J D Rowley
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

View more
  35 in total

1.  Association study of autoimmune thyroid disease at 5q23-q33 in Japanese patients.

Authors:  Takashi Akamizu; Hitomi Hiratani; Satoshi Ikegami; Stephen S Rich; Donald W Bowden
Journal:  J Hum Genet       Date:  2003-04-09       Impact factor: 3.172

2.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

3.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Authors:  Andres Jerez; Lukasz P Gondek; Anna M Jankowska; Hideki Makishima; Bartlomiej Przychodzen; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Denise Batista; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1.

Authors:  C Liu; E Adamson; D Mercola
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

Authors:  N Zhao; A Stoffel; P W Wang; J D Eisenbart; R Espinosa; R A Larson; M M Le Beau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 6.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

7.  PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Authors:  Jianxiu Yu; Sharon S Zhang; Kan Saito; Scott Williams; Yutaka Arimura; Yuliang Ma; Yuehai Ke; Veronique Baron; Dan Mercola; Gen-Sheng Feng; Eileen Adamson; Tomas Mustelin
Journal:  EMBO J       Date:  2008-12-04       Impact factor: 11.598

8.  PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.

Authors:  Donkena Krishna Vanaja; Michael E Grossmann; John C Cheville; Mozammel H Gazi; Aiyu Gong; Jin San Zhang; Katalin Ajtai; Thomas P Burghardt; Charles Y F Young
Journal:  Cancer Invest       Date:  2009-03       Impact factor: 2.176

9.  Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.

Authors:  Timothy A Graubert; Michelle A Payton; Jin Shao; Richard A Walgren; Ryan S Monahan; John L Frater; Mark A Walshauser; Mike G Martin; Yumi Kasai; Matthew J Walter
Journal:  PLoS One       Date:  2009-02-25       Impact factor: 3.240

10.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Authors:  Jillian L Barlow; Lesley F Drynan; Duncan R Hewett; Luke R Holmes; Silvia Lorenzo-Abalde; Alison L Lane; Helen E Jolin; Richard Pannell; Angela J Middleton; See Heng Wong; Alan J Warren; James S Wainscoat; Jacqueline Boultwood; Andrew N J McKenzie
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.